Metabolic Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Metabolic Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Metabolic Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Sector Analysis
NewDiabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
$17,995 | July 2026 This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic macular edema market through 2033. Drug sales in the DME pharmacotherapy market are expected to grow by a significant margin between 2024 and 2034, with an overall compound annual growth rate (CAGR) of 3.4% over the forecast period. In 2024, GlobalData estimated the total DME market to be valued at $4.42 billion across the 7MM, with the US accounting...
-
Sector Analysis
NewType 2 Diabetes (T2D): Epidemiology Forecast to 2035 Type 2 Diabetes (T2D): Epidemiology Forecast to 2035
$9,995 | July 2026 Type 2 diabetes (T2D), formerly known as non-insulin dependent or adult-onset diabetes, is a chronic condition characterized by a non-autoimmune progressive loss of pancreatic beta cells, which produce insulin (Lu et al., 2024; World Health Organization [WHO], 2024). T2D accounts for over 90% of all diabetes cases, with type 1 and gestational diabetes making up the majority of the remaining cases (Goyal, Singhal and Jialal, 2023). T2D most commonly occurs in persons older than 45 years, however its prevalence in...
-
Sector Analysis
NewOverweight and Obesity: Epidemiology Report and Forecast to 2035 Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026 Obesity is a chronic disease characterized by the accumulation of excess body fat. Individuals living with obesity may undergo metabolic dysfunction on account of excess adipose tissue. The diagnostic criteria for obesity are met by a body mass index (BMI) of 30kg/m2 or more (NIH, 2022a). This can lead to a state of chronic systemic inflammation, as well as a predisposition to comorbidities such as diabetes and cardiovascular disease. Clinical interventions aim to manage obesity by encouraging patient behavioral change,...
-
Product Insights
Diabetic Foot Ulcers: Global Clinical Trials Review, 2026 Diabetic Foot Ulcers: Global Clinical Trials Review, 2026
$3,450 | April 2026 GlobalData's clinical trial report, “Diabetic Foot Ulcers - Global Clinical Trials Review, 2026" provides an overview of Diabetic Foot Ulcers Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Ulcers. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Global Clinical Trials Review, 2026 Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Global Clinical Trials Review, 2026
$3,450 | February 2026 GlobalData's clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Global Clinical Trials Review, 2026" provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Hyperlipidemia: Global Clinical Trials Review, 2026 Hyperlipidemia: Global Clinical Trials Review, 2026
$3,450 | February 2026 GlobalData's clinical trial report, “Hyperlipidemia - Global Clinical Trials Review, 2026" provides an overview of Hyperlipidemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperlipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hyperuricemia - Global Clinical Trials Review, 2026 Hyperuricemia - Global Clinical Trials Review, 2026
$3,450 | January 2026 GlobalData's clinical trial report, “Hyperuricemia - Global Clinical Trials Review, 2026" provides an overview of Hyperuricemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperuricemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Phenylketonuria (PKU) - Global Clinical Trials Review, 2025 Phenylketonuria (PKU) - Global Clinical Trials Review, 2025
$3,450 | December 2025 GlobalData's clinical trial report, “Phenylketonuria (PKU) - Global Clinical Trials Review, 2025" provides an overview of Phenylketonuria (PKU) Clinical trials scenario. This report provides top line data relating to the clinical trials on Phenylketonuria (PKU). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034 Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
$9,995 | December 2025 Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Product Insights
Diabetic Peripheral Neuropathy: Global Clinical Trials Review, 2025 Diabetic Peripheral Neuropathy: Global Clinical Trials Review, 2025
$3,450 | November 2025 GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy - Global Clinical Trials Review, 2025" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.